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Background: Acute Myeloid Leukaemia (AML) is a highly heterogeneous disease. Studies in adult AML have identified
epigenetic changes, specifically DNA methylation, associated with leukaemia subtype, age of onset and patient survival
which highlights this heterogeneity. However, only limited DNA methylation studies have elucidated any associations in
paediatric AML.
Methods: We interrogated DNA methylation on a cohort of paediatric AML FAB subtype M5 patients using the Illumina
HumanMethylation450 (HM450) BeadChip, identifying a number of target genes with p <0.01 and Δβ >0.4 between
leukaemic and matched remission (n = 20 primary leukaemic, n = 13 matched remission). Amongst those genes
identified, we interrogate DLEU2 methylation using locus-specific SEQUENOM MassARRAY® EpiTYPER® and an increased
validation cohort (n = 28 primary leukaemic, n = 14 matched remission, n = 17 additional non-leukaemic and cell lines).
Following methylation analysis, expression studies were undertaken utilising the same patient samples for singleplex
TaqMan gene and miRNA assays and relative expression comparisons.
Results: We identified differential DNA methylation at the DLEU2 locus, encompassing the tumour suppressor microRNA
miR-15a/16-1 cluster. A number of HM450 probes spanning the DLEU2/Alt1 Transcriptional Start Site showed increased
levels of methylation in leukaemia (average over all probes >60%) compared to disease-free haematopoietic cells and
patient remission samples (<24%) (p < 0.001). Interestingly, DLEU2 mRNA down-regulation in leukaemic patients (p < 0.05)
was independent of the embedded mature miR-15a/16-1 expression. To assess prognostic significance of DLEU2 DNA
methylation, we stratified paediatric AML patients by their methylation status. A subset of patients recorded methylation
values for DLEU2 akin to non-leukaemic specimens, specifically patients with sole trisomy 8 and/or chromosome
11 abnormalities. These patients also showed similar miR-15a/16-1 expression to non-leukaemic samples, and
potential improved disease prognosis.
Conclusions: The DLEU2 locus and embedded miRNA cluster miR-15a/16-1 is commonly deleted in adult cancers and
shown to induce leukaemogenesis, however in paediatric AML we found the region to be transcriptionally repressed.
In combination, our data highlights the utility of interrogating DNA methylation and microRNA in combination with
underlying genetic status to provide novel insights into AML biology.
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Acute myeloid leukaemia (AML) is the third most common
form of leukaemia in children, typically characterised by the
rapid proliferation of primitive haematopoietic myeloid
progenitor cells [1]. Paediatric AML is a highly heteroge-
neous disease, which presents a major barrier towards
the development of accurate disease classification, risk
stratification and targeted therapies within the clinic.
The French-American-British (FAB) [2] and more re-
cently World Health Organisation (WHO) [3] classifica-
tions of leukaemia take into account cell morphology,
cytogenetic aberrations and common genetic lesions.
However, not all patients fall into these well-defined cat-
egories. Additionally, the recurrent chromosomal and
genetic lesions frequently found in AML fail to induce
leukaemogenesis and do not explain the recognised
clinical heterogeneity [4,5].
One of the hallmarks of nearly all human cancers is
the disruption of the epigenetic profile, including gross
aberrations in DNA methylation. Increasing evidence in
adult AML has indicated that epigenetic events play
critical roles in the onset, progression, and outcome of
AML [6] and may help tailor disease treatment. How-
ever, the need for similar elucidations in childhood
disease is paramount. Aberrant methylation of cytosine res-
idues at palindromic CpG sites (often clustered in dense
CpG ‘islands’) near gene promoter regions is widely
studied in carcinogenesis and haematological malig-
nancies [6,7]. It is now well established that elevated
DNA methylation is an important mechanism of gene
transcriptional inactivation [8,9] and genes such as
ESR1, IGSF4 and CDKN2B/p15 are epigenetically si-
lenced in adult leukaemia [6]. Previous studies have
subdivided adult AML into 16 epigenetic sub-groups
based on DNA methylation signatures, correlating with
patient clinical outcome and distinct from both normal
haematopoietic cells and normal stages of myeloid
differentiation [4]. Despite such emerging findings in
an adult context, the utility of individual DNA methyla-
tion disruptions in paediatric AML has yet to be fully
evaluated [6].
MicroRNA (miRNA) represent an alternative epigen-
etic regulator, having been implicated in the regulation
of critical gene expression networks in plants and ani-
mals. The role of miRNA in haematopoiesis, cancer and
disease is also beginning to be appreciated [10,11]. The
global influence of individual miRNA on the genome is
difficult to dissect, as miRNA can modulate the expres-
sion of hundreds of genes, and each gene can harbour
binding sites for several miRNA [12]. Human miRNA
are initially transcribed (pri-miRNA), and processed by sev-
eral complexes to form a 70 bp hairpin-loop (pre-miRNA)
[13]. After successive enzymatic steps, a miRNA:miRNA*
complementary duplex is formed where the ‘functional’strand is combined with RISC (RNA Induced Silencing
Complex) and Argonaute proteins to guide, and inhibit,
specific target messenger RNA (mRNA) through base pair
recognition [14,15]. However, the miRNA transcriptome
is becoming increasingly complex, emphasised by Next
Generation Sequencing (NGS) technologies. NGS has
highlighted that alternate miRNA* transcripts, as well
as miRNA sequence variants (isomiRs [16]) may play
a biological role, similar to their canonical miRNA
relatives [17,18].
Links between miRNA deregulation and cancer
diagnosis were first identified in adult Chronic Lympho-
blastic Leukaemia (CLL), where the loss or down-
regulation of tumour-suppressing miRNA cluster miR-15a/
16-1 directly caused leukaemic transformation [19,20]. At
present, no such association has been identified for child-
hood leukaemia. The expression of paediatric disease-
associated miRNA has to date only identified a distinction
between leukaemia of different lineages and the differenti-
ation of rearranged AMLs within a limited number of
cytogenetic subtypes [21,22]. Paediatric MLL can be
distinguished from others by differentially expressed
miR-126, miR-146a, miR-181a/b/d, miR-100, miR-21,
miR-196a/b, miR-29 and miR-125b [21]. However con-
cordance among studies is often low and the mechan-
ism of deregulation is often unknown [22,23].
Genes encoding miRNA can be regulated epigeneti-
cally in a similar manner to protein coding genes [22].
Studies have demonstrated epigenetically regulated
miRNA in adult AML, including hypermethylation and
down-regulation of miR-124a and associated deregula-
tion of target mRNA EVI1, CEBPA and CDK6 inde-
pendent of diagnostic cytogenetic subtype (reviewed in
[22]). Additionally, miR-193a targeting KIT, and miR-
14b targeting CREB have been identified in adult inves-
tigations as specifically controlled by DNA methylation
(reviewed in [22]). However, the identification of DNA
methylation and miRNA expression connections in
paediatric leukaemia is lacking.
Paediatric AML has distinct cytogenetic and clin-
ical features relative to their adult counterparts
[5,21,24-26]. Therefore, there is a critical need to im-
prove our understanding of the biology of childhood
leukaemia as separate entities, distinct from adult
disease. Cognisant of this, we aimed to identify differ-
ential DNA methylation within paediatric AML on a
genome-scale using defined clinical subtypes and age-
matched controls. We identified a number of signifi-
cantly altered DNA methylation loci, with associated
gene and miRNA expression change, between paediatric
AML and non-leukaemic counterparts. Specifically we de-
scribe here the epigenetic deregulation of DLEU2, which
has associated alterations in downstream miR-15a/16-1
miRNA cluster expression.
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The DLEU2 gene is specifically hypermethylated and
repressed in paediatric AML subtype M5
The FAB subtype M5 (monocytic/blastic leukaemia) is a
distinct subtype with characteristic chromosomal abnor-
malities including t(8; 16), +8 and various translocations
involving 11q23 and the MLL locus such as t(9;11),
t(10;11), t(11;19) and others [27]. AML subtype M5
also has a high proportion of cytogenetically normal
(CN-AML) patients [27], and those with complex
karyotypes [28]. A combination of these factors add to
the overall unfavourable outcome of paediatric M5
diagnosis [29]. Genome-scale methylation profiling of
AML M5 bone marrow samples identified 3,352 sig-
nificantly differentially methylated probes (DMPs) be-
tween paediatric AML FAB M5 (n = 20) and matching
non-leukaemic (n = 17) samples. Applying more stringent
feature selection criteria of an adjusted p-value <0.01
and Δβ of >0.4 reduced the number of DMPs to 137
(Additional file 1).
The list of DMPs included several localising to the long
non-coding RNA DLEU2 and the embedded miRNA clus-
ter miR-15a/16-1 [19,20], previously implicated in adultFigure 1 Regional interrogation of the DLEU2 gene including significa
analysis. Bottom: Distribution of HM450 methylation probes across the DL
DLEU2, miR15a/16-1 microRNA cluster, TRIM13, KCNRG and miR-3613. Top: H
between paediatric AML (FAB subtype M5) and non-leukaemic specimens
(n = 16) refers to diagnostic bone marrow from paediatric patients. Non-leu
CD33+, CD34+, CD45+) and patient remission specimens. Differential meth
transcript, which also falls into the body region of DLEU1 within 3 CpG isla
95% CI are shown. Data for leukaemic samples are red and non-leukaemic
methylation) to 1.0 (100% fully methylated). Significantly differentially meth
p < 0.001 are highlighted with **.leukaemic [19,20,30]. To date, disruption of this region has
not been observed in paediatric cancers and as such we
chose to focus on DLEU2 in subsequent analysis. A total
of three DLEU2 DMPs had an adjusted p-value <0.01 and
Δβ of >0.4 (cg05394800, cg20529344, cg12883980). These
probes were located within three CpG islands (Chr 13: 50,
690,000-50,708,000: UCSC human hg19 assembly) at the
DLEU2/Alt1 transcriptional start site (TSS) and ‘north
shore’ (Figure 1), a region up to 2 kb upstream from the
DLEU2/Alt1 TSS CpG island under investigation [31].
Henceforth this will be referred to as the DLEU2 promoter.
A divergent DNA methylation profile was observed
between all cases of paediatric AML with elevated
methylation (mean 64% (48-80% CI) across significant
probes and non-leukaemic samples (23% methylation;
7-39% CI of mean) (p < 0.001 for all significant probes)
(Figure 1; Additional file 2). DNA methylation levels at
CpG sites interrogated by cg05394800, cg20529344,
cg12883980 were confirmed using SEQUENOM EpiTY-
PER MassArray (Additional file 3 and Additional file 4) in
the discovery sample set of 20 leukaemic patients and 17
non-leukaemic controls, as well as a validation set of paedi-
atric AML M5 patients with heterogeneous cytogeneticntly differentially methylated probes identified by HM450
EU2 region of 13q4. Genes located in this region include: DLEU1,
M450 probes identified as significantly differentially methylated
have been plotted against genomic location. The leukaemic group
kaemic group (n = 11) consists of CD sorted cell populations (CD19+,
ylation is concentrated in the promoter region of the DLEU2/Alt1 long
nds (Chr 13: 50, 690,000-50,708,000). Mean methylation β values and
samples in green. Methylation values range from 0 (0%, no detected
ylated regions between leukaemic and non-leukaemic samples to
Figure 2 Expression analysis of DLEU2 and miR-15/16 in paediatric
AML. Here we interrogate the gene, miRNA and precursor miRNA
expression in paediatric AML compared to non-leukaemic. This interrogation
includes DLEU2 and embedded miR-15a/16-1 on chromosome 13q4.
The leukaemic group refers to diagnostic bone marrow from paediatric
patients. The non-leukaemic group consists of CD sorted cell populations
(CD19+, CD33+, CD34+, CD45+) and patient remission specimens, and is
represented by the dashed line at Y = 1. Fold Change (FC) is plotted
using normalized data and the 2-ΔΔCt method ± SD, and shows the fold
change calculated from the means of each group. A. Gene expression
including DLEU1, DLEU2 and TRIM13 in paediatric AML (n = 10) compared
to non-leukaemic (n = 13) expression. DLEU2 shows a significant
down-regulation in AML compared to non-leukaemic expression
(0.07 FC, p = 0.014 represented by **), however there is no significant
change in expression for TRIM13 or DLEU1. B. Mature microRNA
expression, including primary precursor transcript (PRI) and alternate
miRNA expression (*), from the miR-15a/16-1 miRNA cluster embedded
within DLEU2 for paediatric AML (n = 28, including the 10 used in
Figure 2A) compared to non-leukaemic specimens (n = 30, including
the 13 used in Figure 2A). Here the miR-15a/16-1 PRI transcript is
3.03-fold higher in expression compared to non-leukaemic expression.
Additionally, miR-16-1* (2.52 FC), miR-15a* (2.24 FC) and miR-15a (1.5 FC)
also show increases in expression in paediatric AML. No significant
change in expression was observed for miR-16 (0.94 FC) in paediatric
AML compared to non-leukaemic expression.
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(n = 2), WT1 (n = 1)) (Additional file 5). This analysis con-
firmed specific DLEU2 promoter hypermethylation in
paediatric AML patients (p < 0.001) (Additional file 4), with
additional genes in this region, including DLEU1, hsa-miR-
15a/16-1 microRNA cluster, TRIM13, KCNRG and hsa-
miR-3613 showing no differences in methylation between
cases and controls (Additional file 6). This highlights the
potential regional specificity of the observed DLEU2methy-
lation change in association with AML.
We observed a significant down-regulation of DLEU2
gene expression in paediatric AML (0.07 Fold Change
(FC); p = 0.014), and a significant inverse correlation be-
tween promoter DNA methylation and gene expression
levels (p = 0.0001, Additional file 7). Recent studies in
adult CLL have also identified a negative correlation be-
tween DLEU2 promoter methylation (DLEU2/Alt1) and
gene expression [32]. Interestingly there was no change
in gene expression for any other genes in this region
(TRIM13 = 1.75 FC; DLEU1 = 1.05 FC. Figure 2A).
DLEU2 and embedded miR-15a/16-1 are regulated
independently in paediatric AML
The miR-15a/16-1 cluster has been described to have
potent tumour suppressor activity, targeting numerous
oncogenic and cell cycle regulatory genes [19,33]. The
cluster is embedded within intron 4 of DLEU2, and has
been speculated that expression is driven by the DLEU2
promoter [20,30]. However, we found no correlation be-
tween DLEU2 expression and miR-15a/16-1 expression
in paediatric AML, nor down-regulation of the miR-15a/
16-1 miRNA cluster in relation to increasing DLEU2
promoter DNA methylation (Figure 2B). In contrast to
previous reports for adult leukaemia, no significant change
in mature miR-16 expression was observed between paedi-
atric AML and control samples, a result we have reported
elsewhere [34]. These observations are independent of
the homologous miR-16 cluster embedded in SMC4 on
chromosome 3q26, which shows no significant expres-
sion or DNA methylation changes in association with
AML (Additional file 8). Similar results have been reported
for adult CLL [32]. Taken together this data suggests an
alternate mode of regulation for the miR-15a/16-1 cluster,
outside of the DLEU2 promoter region.
Interestingly, recent research has indicated the processing
mechanisms of miRNA may be affected by cancer, such
that mature miRNA expression becomes disassociated from
precursor miRNA levels, and also from the levels of the
host gene [35]. We found the miR-15a/16-1 primary pre-
cursor transcript is in fact expressed up to three-fold higher
in AML patients compared to non-leukaemic counterparts
(Figure 2B). The increase in primary transcript appears to
correspond to an increase in mature miR-16-1* (2.52 FC)
and miR-15a* (2.2 FC) expression, and a moderate increase
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show differential degrees of over-expression of one, or
all, of the mature species despite the common precursor
(Additional file 9).
Canonical miR-15a/16-1 microRNA species target nu-
merous oncogenic and integral cell cycle regulatory
genes such as BCL-2, MCL-1, CCND1, CDK6, BMI-1,
RASSF5, IGSF4, c-MYB and WNT3A [33,36-42]. To iden-
tify the potential significance of increasing alternate
miR-15a/16-1 transcripts over their canonical counter-
parts in paediatric AML, we investigated miRNA target
genes using prediction tools, and undertook gene ontol-
ogy analysis. We found miR-16-1* is three-fold enriched
for targeting components of the RNA processing and
splicing machinery such as hnRNP regulators, SRRM1
and NUDT2. Down-regulation of these genes by increased
expression of a targeting miRNA may be contributing to
miRNA/host gene disassociation in DLEU2/miRNA-15a/
16-1 expression (Additional file 10). One target of miR-15a*
was found to be ADORA2A, an important G-protein recep-
tor critical in tissue-specific and systemic inflammatory
responses [43,44]. We have identified the down-regulation
of ADORA2A expression within paediatric AML, not me-
diated through DNA methylation, but potentially through
the up-regulation of the miR-15a/16-1 cluster (data not
shown). Moreover, miR-15a* and miR-16-1* are 60–90 fold
enriched for targeting genes involved in the intrinsic
apoptotic pathway such as BCL-2 L11, PPIF and DNM1L
(Additional file 10). The inhibition of these genes to act
upon the cell, mediated through targeting miRNA, can po-
tentially encourage continued cell growth and perpetuation
of AML, through negating apoptotic signalling. The over
expression of alternate mature miRNA in paediatric AML
may also have consequences for integral cell cycle path-
ways, but through different mechanisms to their canonical
counterparts.DLEU2 interrogation identifies a novel subclass of
paediatric AML
In addition to assessing the association of DLEU2 promoter
DNA methylation and miR-15a/16-1 miRNA expression
with paediatric AML, we also assessed correlations with
distinct clinical and diagnostic variables. We found no sig-
nificant association between DLEU2 methylation/expres-
sion with sex, age of disease onset or relapse status nor
common gene abnormalities such as FLT3 or MLL, as has
been found in a number of other association studies [6,45].
DLEU2 methylation clustering based on diagnostic FAB
subtype revealed a wide range of values (M5a: 16-91%;
M5b: 48-90%; ‘Other’ subtypes: 51-93%. Additional file 11),
indicating mean methylation in isolation does not stratify
paediatric AML subtype. Additionally, we found there to be
no correlation between percentage of leukaemic blasts atpatient diagnosis and the DNA methylation status at the
DLEU2 promoter region (data not shown).
Previous adult leukaemia studies have identified novel
methylation subgroups, independent of cytogenetic pro-
file [4,46]. We identified a subset of patients displaying
low DLEU2 promoter methylation comprising patients
with trisomy 8 and/or chromosome 11q abnormalities,
independent of MLL rearrangements (separated into a t
(11)/+8 subgroup - Figure 3A, Additional file 11). This
delineation identified t(11)/+8 subgroup as having com-
parable DLEU2 methylation levels to non-leukaemic
specimens (Figure 3B), and significantly lower methyla-
tion compared to the remaining paediatric AML samples
(M5a/b p < 0.05; M1/M2/M4 p < 0.0001 Figure 3B). Classi-
fying t(11)/+8 patients as a separate subgroup further
delineated M5a, M5b and M1/M2/M4 AML patients from
non-leukaemic counterparts according to average methyla-
tion status (M5a MM= 0.81, M5b MM=0.78, M1/M2/M4
MM=0.87. p < 0.0001. Figure 3B).
Cases carrying 11q rearrangements are the most het-
erogeneous of paediatric AML [27,29,47], linked to
50–104 translocation fusion partners to date [29,46,48].
Trisomy 8 is a frequently reported aberration in adult
and paediatric AML [29]. However little is known about
the gain of chromosome 8 in isolation and its relation-
ship to disease onset. As such this has been speculated
to be a disease modulating secondary event [49]. Lower
DNA methylation in the t(11)/+8 subgroup may poten-
tially confer a better prognosis, as it is well documented
that hypermethylation of the DLEU2 region is involved
in leukaemic transformation in adults [19,20,30]. Ana-
lysis of the t(11)/+8 subgroup in isolation also revealed
no significant miRNA expression differences relative to
non-leukaemic samples (Figure 4A), and it is well docu-
mented that miR-15a/16-1 abnormalities are also associ-
ated with leukaemic transformation in adults [19,20].
We additionally identified a trend towards decreased risk
of relapse in t(11)/+8 subgroup compared to other sub-
types, and a trend towards better survival outcomes
(Additional file 12). These analyses combined may elu-
cidate a connection between DLEU2 promoter DNA
methylation (Figure 3B), miRNA expression (Figure 4A)
and prognostic outcomes for this subgroup of paediat-
ric AML (Additional file 12).
The classification of t(11)/+8 cases as an independent
subgroup revealed a significant increase in pri-miR-15a
expression in traditional FAB subtype M5b from non-
leukaemic (20.29-fold, p < 0.001; Figure 4C) and from
M5a/M1/M2/M4 (Figure 4B). The increase translates to
a >2-fold increase in miR-15a, 4.87-fold increase in miR-
15a*, and 9.86-fold increase in miR-16-1* expression.
Based on DLEU2 DNA methylation status, in conjunc-
tion with miRNA expression analysis, we speculate that
pri-miR-15a expression alone may be a useful biomarker
Figure 3 Interrogation of paediatric AML by clinically defined cytogenetic and FAB subtypes alongside DLEU2 promoter methylation.
Paediatric AML diagnostic cytogenetic and subtyping analyses were specifically investigated, including those with known gene abnormalities
and CN-AML cases. We investigate here the DNA Methylation of DLEU2/Alt1 promoter region to 95% CI. DNA methylation values range from 0.0
(0% no detected methylation) to 1.0 (100% fully methylated). The leukaemic group refers to diagnostic bone marrow from paediatric patients.
Non-leukaemic group consists of CD sorted cell populations (CD19+, CD33+, CD34+, CD45+) and patient remission specimens. A. DNA methylation for
DLEU2 HM450 probes (cg12883980, cg20529344, cg5394800) according to cytogenetic type, showing heterogeneous DNA methylation outcomes. Of note,
a subset of patients with observable chromosome 11 and trisomy 8 abnormalities have a reduced DNA methylation compared to all other
AML abnormalities. B. A subset of DLEU2 DNA methylation results for paediatric AML chromosome 11 and trisomy 8 abnormality patients
from Figure 3A fall into a range akin to non-leukaemic specimens. Grouping these patients, regardless of clinical subtyping (M5a, M5b or
M1/M2/M4), forms an additional sub-group, denoted here as ‘t(11)/+8’. The DNA methylation values obtained for probe cg12883980 are
depicted, as an indication of the methylation at the DLEU2 promoter. t(11)/+8 are not differentially methylated compared to non-leukaemic
specimens (t(11)/+8 sub-group Mean Methylation (MM) = 0.38, non-leukaemic MM= 0.32. p = 0.22). M5a, M5b and M1/M2/M4 AMLs (with the removal of
t(11)/+8 patients) have become increasingly hypermethylated compared to non-leukaemic methylation (M5a MM= 0.81, M5b MM= 0.78, M1/M2/M4
MM= 0.87. p < 0.0001), and significantly different from t(11)/+8 (M5a/b p < 0.05; M1/M2/M4 p< 0.0001).
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subtypes.
Conclusions
Previous research within paediatric AML has shown that
well-defined cytogenetic subgroupings exhibit a wide
range of genomic and epigenomic heterogeneity. Linking
specific epigenetic features to clinical parameters has the
potential to identify pathological drivers of disease and
develop enhanced molecular approaches for diagnosis,
prognosis and refinement of treatment. Profiling epigenetic
regulators has provided clinically relevant biomarkers for
adult cancers; however generally the same cannot be said of
childhood cancers. Our analysis has identified hypermethy-
lation induced down-regulation of the DLEU2 gene in
paediatric AML. The related expression changes of the
embedded miR-15a/16-1 microRNA cluster in paediatric
AML has the potential to contribute to leukaemic trans-
formation, with a switch from canonical to alternate
miRNA family members, which in turn may modulate the
expression of downstream regulatory genes. Treating
paediatric AML model systems with epigenetic modifying
drugs will allow a more comprehensive analysis towards
the clinical applications and potential patient-focussed
therapeutic interventions for children. Our results high-
light the need for further specific interrogation of paediatric
AML subtypes as distinctive biological entities, separatefrom adult disease. Further studies utilising larger patient
cohorts are required to explore the complex interplay
between the epigenetic regulation of genes harbouring




This study was approved by the Royal Children’s Hospital
(RCH), Melbourne, Ethics Committee (HREC reference
#27138E). Samples used consisted of snap frozen bone mar-
row specimens and archived bone marrow biopsies taken
at diagnosis, patient remission/follow-up or at relapse from
paediatric acute myeloid leukaemia (AML) cases. The diag-
nosis of AML was established according to the criteria of
the French–American–British (FAB) classification by stand-
ard morphological and cytological methods. The evaluation
for mutations in MLL, FLT3, RUNX1 and WT1 genes were
assessed in a small number of patients as a part of the ini-
tial assessment. No patient recorded any chromosome 13
deletions or abnormalities listed in their clinical diagnoses.
The median percentage of leukaemic blasts at patient diag-
nosis is 88% (67–93 95% CI).
Patient samples used in our study consisted of archived,
air-dried bone marrow smear slides. The utility of these
samples for DNA methylation and miRNA expression ana-
lysis has been outlined previously [34,50]. Cryogenically
Figure 4 Gene, primary, miRNA and miRNA* expression for paediatric AML defined through clinical classification and DLEU2
Methylation subtyping. Mature microRNA expression, primary precursor transcript (PRI) and alternate miRNA isoform expression (*) from the
miR-15a/16-1 miRNA cluster embedded within DLEU2 for paediatric AML patients (n = 26: 12 M5a, 5 M5b, 4 M1/M2/M4, 5 t(11)/+8 sub-group) all
compared to non-leukaemic specimens (n = 30). Leukaemic groups refer to diagnostic bone marrow from paediatric patients. Non-leukaemic
group consists of CD sorted cell populations (CD19+, CD33+, CD34+, CD45+)and patient remission specimens. Linear Fold Change (FC) is plotted
using normalized data and the 2-ΔΔCt method ± SD, and shows the fold change calculated from the means of each group. DLEU2 gene expression
is down-regulated in all subtypes. A. Fold change in expression comparing non-leukaemic to t(11)/+8 subtype. No significant differences in RNA
expression are observed between non-leukaemic specimens and this subgroup. B. Fold change in expression comparing patients from subtype
M5a to M1/M2/M4. DLEU2 is down-regulated in all subtypes (as previously described in Figure 2), and primary precursor for miR-15a also appears
down-regulated (non-significant). M1/M2/M4 groupings do not show any mature miRNA expression changes (defined as >2-fold difference from
non-leukaemic). Subtype M5a shows a 2.1-fold (±0.8 SD) increase in miR-15a* and a 2.81-fold (±0.4 SD) increase in miR-16-1*. C. FAB subtype M5b
shows up-regulation of miR-15a PRI compared to non-leukaemic expression (20.29-fold (±0.6 SD) p < 0.001), with miR-15a* (4.87-fold ±1 SD) and
miR-16-1* (9.86-fold ±1 SD) also up-regulated. M5b additionally shows a significant up-regulation of miR-15a PRI compared to t(11)/+8 sub-group
samples (p < 0.05), and also from M5a and M1/M2/M4 sub-groups (p < 0.001).
Morenos et al. Molecular Cancer 2014, 13:123 Page 7 of 11
http://www.molecular-cancer.com/content/13/1/123frozen patient bone marrows were also used where
available. All patients were <18 years of age. We chose
to focus specifically on the FAB subtype M5 (a and b)
as it is a common subtype. Our cohort included com-
parable ratios between males and females, and also
similar numbers of children that relapsed or not.
(Additional file 5). Control samples from bone marrow
of unrelated and unaffected children were analysed in
parallel, as well as multiple cell lines, including adult
leukaemia (REH [51], CCRF-CEM [52]), paediatric
AML (Kasumi-1 [53], THP-1 [54], MV-4-11 and AML-
193 [55]) obtained from American Type Culture Col-
lection (ATCC) and subjected to characterisation usingthe ATCC Proficiency Standard program. Fluorescent
Activated Cell Sorted (FACS) isolated haematopoietic
progenitor cell populations from unrelated and unaffected
paediatric donors (CD19+, CD33+, CD34+ and CD45+
populations, from herein known as CD sorted cells),
were also used in this study. Our ‘non-leukaemic’
group consisted of all individual CD sorted cell popula-
tions as well as non-leukaemic remission and follow-
up slides and bone marrow from paediatric patients.
We compared the DLEU2/Alt1 DNA methylation for
all ‘non-leukaemic’ specimens, and found no signifi-
cant differences across these non-leukaemic samples
(Additional file 13).
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Genomic DNA was extracted using the phenol/chloro-
form method and bisulphite converted in accordance
with manufacturer’s protocols, as reported previously [23].
DNA extracts were checked for quality and quantity using
a NanoDrop® ND-1000 spectrophotometer (Thermo Fisher
Scientific Inc., Scoresby, Victoria, Australia). All DNA was
stored at −80°C.
Bisulphite conversion of genomic DNA was performed
using the MethylEasy Xceed Bisulfite Modification Kit
(Human Genetic Signatures, Sydney, AUST). The con-
verted samples were processed by the Australian Genome
Research Facility (AGRF, Melbourne, Australia) and ana-
lysed using the Illumina HumanMethylation450 (HM450)
Bead Chip arrays according to manufacturer’s protocol.
Illumina Genome Studio software was used to extract the
raw M-values and probe intensities for downstream pro-
cessing. Samples with a probe p-detection value of p <0.05
were retained. Data were quantile normalized using lumi
[56] and analysed using LIMMA [57]. All analysis was
performed using the R statistical software package on
M-values that were converted to β-values (0 = unmethy-
lated, 1 = fully methylated) for reporting and biological
interpretation. To eliminate sex bias, probes hybridizing to
sex chromosomes were filtered out, leaving 366,553 probes
common to all samples in the final dataset. Further filtering
was based on the degree of difference in β between sample
groups, indicated as Δβ calculated using the formula:
Δβ ¼ meanβvalue Leukaemicð Þ−meanβvalue Non−Leukaemicð Þ
SEQUENOM MassARRAY® EpiTYPER® was used to
measure locus-specific methylation. Sixty-one samples
were analysed, including the 42 analysed on the HM450
platform (Additional file 5), an additional 3 cell lines,
8 leukaemic and 8 non-leukaemic whole bone marrow
aspirate samples. Primers for analysis were designed using
SEQUENOM EpiDesigner software (www.epidesigner.com)
and the sequences for these are listed in Additional file 14.
Gene ontology and pathway analysis of genes associated
with significantly altered DNA methylation probes were
analysed through the use of IPA (Ingenuity® Systems,
www.ingenuity.com) and GOrilla [58].
RNA extraction, quality control and expression analysis
Small RNA extraction was performed using TRIzol®
(Ambion®) for patient bone marrow samples, mononuclear
cells and cell lines in accordance with the manufacturer’s
instructions, or the High Pure miRNA Isolation Kit
(Roche) for archived slide samples as previously described
[34]. Before RNA extraction of fresh bone marrow aspi-
rates, samples were processed using Ficoll-Paque™ (GE
Healthcare, Piscataway USA) to isolate the mononuclear
cell population. This was immediately cryo-frozen or storedin RNAlater® (Ambion® by Life Technologies, Mulgrave,
Victoria Australia) for later extraction. The concentration
and purity of all RNA samples was assessed using the
NanoDrop® ND-1000 spectrophotometer (Thermo Fisher
Scientific Inc., Scorsby, Victoria, Australia). All RNA was
stored at −80°C.
Seventy samples were used in the interrogation of
miRNA expression, 64 of which were also used for HM450
and SEQUENOM methylation analysis (Additional file 5).
TaqMan® MicroRNA Reverse Transcription kit and single-
plex TaqMan ® microRNA Assays (Applied Biosystems, Life
Technologies) (assays listed in Additional file 15) were
utilised according to the manufacturer’s instructions
before routine quantitative real-time PCR (qRT-PCR)
was performed using Applied Biosystems 7300 Se-
quence Detection System. A subset of 29 high quality
samples which included all cell lines as previously de-
scribed, CD19+, CD33+, CD34+, CD45+ as well as 8
leukaemic and 9 non-leukaemic patient whole bone mar-
rows, were used for gene and pri-miR expression analysis.
This was due to longer RNA species often being degraded
in archived specimens [59,60]. The SuperScript® VILO™
cDNA Synthesis Kit (Life Technologies) and TaqMan® gene
expression assays were used for gene/pri-miR expression as
per manufacturer’s instructions (Additional file 15 and
Additional file 16) before performing qRT-PCR analysis ac-
cording to the manufacturer’s instructions. All qRT-PCR
samples were analysed in duplicate.
Expression data was normalized using the synthetic small
nucleolar RNA, C/D Box 44 (RNU44) and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) for gene/pri-miR
expression; and RNU44 and hsa-miR-26b for miRNA ana-
lysis, previously identified as having the greatest stability in
our samples [34]. Data were analysed using DataAssist™
software (v.3.0, Applied Biosystems, Life Technologies:
www.lifetechnologies.com/au/en/home/technical-resources/
software-downloads/dataassist-software), and all p-values
were adjusted using Benjamini-Hochberg False Discov-
ery Rate.
All analyses used the combined average of non-
leukaemic primary bone marrow tissue and CD sorted
non-leukaemic cell expression values as the Reference
Group (calibrator). Fold Change (FC) was calculated
using the Livak method of 2-ΔΔCt [61] plotting fold
change and associated p-values. The fold change re-
ported here is the difference of the means of each
group, and a fold change of >2 between disease and
non-leukaemic groups were considered noteworthy.
microRNA gene target prediction was assessed using
microRNA.org [62,63] and miRWalk [64]. The top 500
target genes for each miRNA (Additional file 17) were
used for gene ontology/pathway analysis (Additional
file 10) by IPA (Ingenuity® Systems, www.ingenuity.com)
and GOrilla [58].
Morenos et al. Molecular Cancer 2014, 13:123 Page 9 of 11
http://www.molecular-cancer.com/content/13/1/123Statistical methods
Where groups were compared with more than one vari-
able measured (non-repeated measures), a Two-Way
ANOVA with Bonferroni Post-testing was performed.
Where groups were compared with only one variable
measured, a Kruskal-Wallis test was performed with
Dunns Post-testing. These analyses were undertaken on
normalized data. Correlation assessments utilised Spear-
man Rank tests. Two-tailed p-values were utilised for
assessment of statistical significance, and results with
p-values p < 0.05 were considered to be statistically sig-
nificant. Survival and relapse curves were estimated by
the Kaplan-Meier method. Statistical analyses were per-
formed with GraphPad PRISM (Version 5) for Windows,
(GraphPad Software, USA, www.graphpad.com). CI re-
fers to 95% Confidence Intervals.Additional files
Additional file 1: HM450 methylation heat map of the top 137
significantly differentially methylated probes between paediatric
AML (FAB subtype M5) compared to non-leukaemic controls.
Additional file 2: Paediatric AML DNA methylation results compared
to non-leukaemic methylation for the differentially methylated probes
identified using HM450.
Additional file 3: DNA methylation cross-platform validation between
HM450 and SEQUENOM MassARRAY® EpiTYPER®.
Additional file 4: CpG locations captured by SEQUENOM MassARRAY®
EpiTYPER®, including the HM450 probes.
Additional file 5: Patient information for all paediatric AML patients
used for HM450 DNA methylation interrogation, SEQUENOM
MassARRAY® EpiTYPER® validation and gene expression analysis.
Additional file 6: HM450 probe methylation values for the 13q4
region for paediatric AML (FAB M5) compared to non-leukaemic
controls.
Additional file 7: Correlation between DLEU2/Alt1 promoter DNA
methylation and DLEU2 gene expression.
Additional file 8: HM450 probe methylation and expression
dynamics of paediatric AML compared to non-leukaemic controls
for the alternate miR-16 cluster, miR-15b/16-2 embedded in SMC4
on chromosome 3.
Additional file 9: Comparison of individual patient miRNA miR-15a/
16-1 cluster expression.
Additional file 10: Top Gene Ontology terms using GOrilla gene
ontology identification tool.
Additional file 11: DLEU2 promoter DNA methylation divided into
paediatric AML patient clinical diagnostic observations.
Additional file 12: Survival and relapse curves of paediatric AML,
including a newly defined sub-group based on DLEU2 promoter
DNA methylation.
Additional file 13: DLEU2 DNA methylation comparison of the three
‘non-leukaemic’ sample types.
Additional file 14: Probes used in SEQUENOM MassARRAY®
EpiTYPER® validation analysis of DLEU2/Alt1 HM450 promoter
probes located on Chromosome 13.
Additional file 15: miR-15a/16-1 cluster TaqMan® microRNA and
primary precursor expression assays utilized, including
Normalization references.
Additional file 16: TaqMan® gene expression assays utilized.Additional file 17: The top 500 potential target genes identified for
each differentially expressed miR-15a/16-1 cluster microRNA
member in paediatric AML.
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